Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps

Andrea Baragetti, Daniela Grejtakova, Manuela Casula, Elena Olmastroni, Gloria Saccani Jotti, Giuseppe Danilo Norata, Alberico L. Catapano, Stefano Bellosta

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

After more than a decade of intense investigation, Pro-protein Convertase Subtilisin-Kexin type 9 (PCSK9) remains a hot topic of research both at experimental and clinical level. Interestingly PCSK9 is expressed in different tissues suggesting the existence of additional function(s) beyond the modulation of the Low-Density Lipoprotein (LDL) receptor in the liver. Emerging data suggest that PCSK9 might play a role in the modulation of triglyceride-rich lipoprotein (TGRL) metabolism, mainly Very Low-Density Lipoproteins (VLDL) and their remnants. In vitro, PCSK9 affects TGRLs production by intestinal cells as well as the catabolism of LDL receptor homologous and non-homologous targets such as VLDL receptor, CD36 and ApoE2R. However, the in vivo relevance of these findings is still debated. This review aims at critically discussing the role of PCSK9 on TGRLs metabolism with a major focus on the impact of its genetic and pharmacological modulation on circulating lipids and lipoproteins beyond LDL.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalPharmacological Research
Volume130
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Lipoproteins
Triglycerides
LDL Receptors
Subtilisin
VLDL Lipoproteins
LDL Lipoproteins
Pharmacology
Lipids
Proprotein Convertase 9
Liver
Research
Proteins

Keywords

  • Lipoproteins
  • Metabolism
  • Monoclonal antibodies
  • PCSK9
  • Triglycerides

ASJC Scopus subject areas

  • Pharmacology

Cite this

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism : Facts and gaps. / Baragetti, Andrea; Grejtakova, Daniela; Casula, Manuela; Olmastroni, Elena; Jotti, Gloria Saccani; Norata, Giuseppe Danilo; Catapano, Alberico L.; Bellosta, Stefano.

In: Pharmacological Research, Vol. 130, 01.04.2018, p. 1-11.

Research output: Contribution to journalReview article

Baragetti, Andrea ; Grejtakova, Daniela ; Casula, Manuela ; Olmastroni, Elena ; Jotti, Gloria Saccani ; Norata, Giuseppe Danilo ; Catapano, Alberico L. ; Bellosta, Stefano. / Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism : Facts and gaps. In: Pharmacological Research. 2018 ; Vol. 130. pp. 1-11.
@article{e2451066f15745a89d114ea21104a6c4,
title = "Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps",
abstract = "After more than a decade of intense investigation, Pro-protein Convertase Subtilisin-Kexin type 9 (PCSK9) remains a hot topic of research both at experimental and clinical level. Interestingly PCSK9 is expressed in different tissues suggesting the existence of additional function(s) beyond the modulation of the Low-Density Lipoprotein (LDL) receptor in the liver. Emerging data suggest that PCSK9 might play a role in the modulation of triglyceride-rich lipoprotein (TGRL) metabolism, mainly Very Low-Density Lipoproteins (VLDL) and their remnants. In vitro, PCSK9 affects TGRLs production by intestinal cells as well as the catabolism of LDL receptor homologous and non-homologous targets such as VLDL receptor, CD36 and ApoE2R. However, the in vivo relevance of these findings is still debated. This review aims at critically discussing the role of PCSK9 on TGRLs metabolism with a major focus on the impact of its genetic and pharmacological modulation on circulating lipids and lipoproteins beyond LDL.",
keywords = "Lipoproteins, Metabolism, Monoclonal antibodies, PCSK9, Triglycerides",
author = "Andrea Baragetti and Daniela Grejtakova and Manuela Casula and Elena Olmastroni and Jotti, {Gloria Saccani} and Norata, {Giuseppe Danilo} and Catapano, {Alberico L.} and Stefano Bellosta",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.phrs.2018.01.025",
language = "English",
volume = "130",
pages = "1--11",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism

T2 - Facts and gaps

AU - Baragetti, Andrea

AU - Grejtakova, Daniela

AU - Casula, Manuela

AU - Olmastroni, Elena

AU - Jotti, Gloria Saccani

AU - Norata, Giuseppe Danilo

AU - Catapano, Alberico L.

AU - Bellosta, Stefano

PY - 2018/4/1

Y1 - 2018/4/1

N2 - After more than a decade of intense investigation, Pro-protein Convertase Subtilisin-Kexin type 9 (PCSK9) remains a hot topic of research both at experimental and clinical level. Interestingly PCSK9 is expressed in different tissues suggesting the existence of additional function(s) beyond the modulation of the Low-Density Lipoprotein (LDL) receptor in the liver. Emerging data suggest that PCSK9 might play a role in the modulation of triglyceride-rich lipoprotein (TGRL) metabolism, mainly Very Low-Density Lipoproteins (VLDL) and their remnants. In vitro, PCSK9 affects TGRLs production by intestinal cells as well as the catabolism of LDL receptor homologous and non-homologous targets such as VLDL receptor, CD36 and ApoE2R. However, the in vivo relevance of these findings is still debated. This review aims at critically discussing the role of PCSK9 on TGRLs metabolism with a major focus on the impact of its genetic and pharmacological modulation on circulating lipids and lipoproteins beyond LDL.

AB - After more than a decade of intense investigation, Pro-protein Convertase Subtilisin-Kexin type 9 (PCSK9) remains a hot topic of research both at experimental and clinical level. Interestingly PCSK9 is expressed in different tissues suggesting the existence of additional function(s) beyond the modulation of the Low-Density Lipoprotein (LDL) receptor in the liver. Emerging data suggest that PCSK9 might play a role in the modulation of triglyceride-rich lipoprotein (TGRL) metabolism, mainly Very Low-Density Lipoproteins (VLDL) and their remnants. In vitro, PCSK9 affects TGRLs production by intestinal cells as well as the catabolism of LDL receptor homologous and non-homologous targets such as VLDL receptor, CD36 and ApoE2R. However, the in vivo relevance of these findings is still debated. This review aims at critically discussing the role of PCSK9 on TGRLs metabolism with a major focus on the impact of its genetic and pharmacological modulation on circulating lipids and lipoproteins beyond LDL.

KW - Lipoproteins

KW - Metabolism

KW - Monoclonal antibodies

KW - PCSK9

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=85042233428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042233428&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2018.01.025

DO - 10.1016/j.phrs.2018.01.025

M3 - Review article

AN - SCOPUS:85042233428

VL - 130

SP - 1

EP - 11

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -